SIX Swiss Exchange · Healthcare
Invest in Molecular Partners stock from India
Indian and foreign residents can buy Molecular Partners (MOLN) shares directly through Paasa.
By Paasa · Updated
Molecular Partners at a glance
- Price
- CHF 3.34+CHF 0.03 (0.91%)
- Market cap
- CHF 125.29M
- Day range
- CHF 3.25 – CHF 3.36
- P/E
- -2.46
- Dividend yield
- None
- Volume
- 1.42K
- 1 month
- -7.99%
- 6 months
- +2.77%
- YTD
- -1.47%
- 1 year
- +15.97%
- 5 years
- -81.67%
Molecular Partners statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 0.0 | CHF 5.0M | CHF 7.0M | CHF 189.6M | CHF 9.3M |
| Gross profit | −CHF 2.1M | −CHF 42.5M | −CHF 40.8M | CHF 138.8M | −CHF 46.4M |
| Operating income | −CHF 55.4M | −CHF 61.2M | −CHF 61.1M | CHF 116.6M | −CHF 63.4M |
| Net income | −CHF 61.7M | −CHF 54.0M | −CHF 62.0M | CHF 117.9M | −CHF 63.8M |
| Earnings per share | −CHF 1.65 | −CHF 1.59 | −CHF 1.89 | CHF 3.63 | −CHF 2.06 |
| EBITDA | −CHF 53.3M | −CHF 51.6M | −CHF 59.5M | CHF 119.0M | −CHF 60.7M |
| Total assets | CHF 102.1M | CHF 158.5M | CHF 198.4M | CHF 262.3M | CHF 172.7M |
| Total debt | CHF 3.6M | CHF 2.4M | CHF 3.7M | CHF 4.8M | CHF 6.0M |
| Cash and short-term investments | CHF 93.1M | CHF 149.4M | CHF 186.9M | CHF 249.1M | CHF 132.8M |
| Shareholders' equity | CHF 80.3M | CHF 141.6M | CHF 176.4M | CHF 235.2M | CHF 107.3M |
| Operating cash flow | −CHF 49.5M | −CHF 59.2M | −CHF 59.0M | CHF 118.6M | −CHF 91.0M |
| Free cash flow | −CHF 50.2M | −CHF 60.0M | −CHF 59.8M | CHF 117.1M | −CHF 92.3M |
| Capital expenditure | −CHF 714.0K | −CHF 723.0K | −CHF 575.0K | −CHF 1.4M | −CHF 1.3M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| DocMorris | DOCM.SW | CHF 13.23 | CHF 646.80M |
| Santhera Pharmaceuticals | SANN.SW | CHF 15.20 | CHF 225.44M |
| Ascom | ASCN.SW | CHF 5.78 | CHF 197.45M |
| Newron Pharmaceuticals | NWRN.SW | CHF 8.35 | CHF 173.73M |
| SHL Telemedicine | SHLTN.SW | CHF 1.07 | CHF 39.65M |
| Relief Therapeutics | RLF.SW | CHF 2.89 | CHF 36.28M |
| EvoNext | EVE.SW | CHF 2.17 | CHF 15.65M |
| Addex Therapeutics | ADXN.SW | CHF 0.02 | CHF 3.13M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 0 buy · 2 hold · 0 sell. Consensus: Hold.
Published sell-side 12-month targets in CHF, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Molecular Partners from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search MOLN and buy
Find Molecular Partners by name or by its ticker, MOLN, and place your order.
Why invest in Molecular Partners from India
What Molecular Partners does
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Molecular Partners operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Molecular Partners stock from India?
Yes. Indian residents and NRIs can buy Molecular Partners (MOLN) shares directly through Paasa. Molecular Partners is listed on the SIX Swiss Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Molecular Partners shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.